-

Cresco Labs Opens Sunnyside Destin and St. Petersburg Florida Stores, Expanding Nationwide Retail Footprint to 66 Locations

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “the Company”), a vertically integrated, multi-state operator and the cannabis industry’s No. 1 producer of branded products, today announced it has expanded its Sunnyside brand in Florida with the opening of two new stores in Destin at 661 Harbor Blvd. and St. Petersburg at 8123 4th St. North. The Company’s Florida retail footprint is now 31 dispensaries. Nationwide, Cresco has 66 operating locations.

“We continue to invest wisely in significant growth states like Florida which has a continuously growing medical market of over 825,000 qualified patients and the possibility of a 2024 adult-use ballot initiative,” said Charlie Bachtell, Cresco Labs’ CEO & Co-Founder. “Both the Pandhandle and Tampa Bay areas are ideal markets to expand our retail brand and product offering, and we found two great locations on major retail corridors where locals and visitors enjoy shopping, eating and entertainment. Our team is thrilled to start helping patients with their everyday cannabis needs.”

This is the first Sunnyside in Destin that joins other stores in Tallahassee, Panama City and Pensacola (9th Ave. and Nine Mile R.) in serving patients in the Panhandle region. In St. Petersburg, this is the Company’s second location strategically located on the north side of the city to serve patients in the Tampa Bay region alongside Sunnyside St. Petersburg South and Clearwater stores.

Both Sunnyside Destin and Sunnyside St. Petersburg North will provide a wide assortment of accessories and products from the Company’s branded portfolio that includes Cresco, One Plant, Supply (High Supply), Good News, Remedi and Sunnyside. Patients can now enjoy more flavors from Sunnyside’s Chews edibles line, which already accounts for 10% of Sunnyside sales in the state, as well as additional flavors and effects from Good News, such as Vegas which boasts elevated effects with caffeine.

Patients can place orders today both in store and online through the retailer’s Sunnyside.shop website. Store hours are Monday through Saturday, 9 AM to 8 PM, and Sunday, 9 AM to 6 PM.

For more information, visit www.Sunnyside.shop.

About Cresco Labs

Cresco Labs is one of the largest vertically integrated, multi-state cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco®, High Supply®, Mindy’s™, Good News®, Remedi™, Wonder Wellness Co.® and FloraCal Farms®. Cresco Labs’ national dispensary brand, Sunnyside®, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED™, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Facebook: Cresco Labs
Twitter: Cresco Labs
LinkedIn: Cresco Labs

Contacts

Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com

Investors:
Megan Kulick, Cresco Labs
Senior Vice President, Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

Cresco Labs

CNSX:CL

Release Summary
Cresco Labs Opens Sunnyside Destin and St. Petersburg Florida Stores, Expanding Nationwide Retail Footprint to 66 Locations
Release Versions

Contacts

Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com

Investors:
Megan Kulick, Cresco Labs
Senior Vice President, Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

More News From Cresco Labs

Cresco Labs Announces Filing of Management Information Circular for Annual General and Special Meeting

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced that it has filed its Management Information Circular (the "Circular") and related proxy materials for its annual general and special meeting of shareholders to be held on October 30, 2026 (the “Meeting”), as it prepares for a potential listing on a senior U.S. exchange. At the Meeting, shareholders will be asked to approve three special resolutions relating to: (1) a...

Cresco Labs Appoints Edward Tilly to Board of Directors

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced the appointment of Edward Tilly to its Board of Directors, effective September 18, 2026. Mr. Tilly will serve as an independent director and join the Audit Committee, bringing the Board to eight directors. Mr. Tilly is a financ...

Cresco Labs Acquires Nine Pennsylvania Dispensaries in Accretive Transaction to Strengthen Market Leadership

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania, advancing Cresco’s leadership position in the second-largest medical marijuana market, wh...
Back to Newsroom